human Microvessel Culture System (hMCS)

人类微血管培养系统 (hMCS)

• 批准号: 8521734
• 负责人: JAMES B HOYING
• 金额: $ 9.95万
• 依托单位: ANGIOMICS, INC.
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-07-16 至 2014-12-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8521734
• 关键词: 3-Dimensional; Angiopoietin-1; Angiopoietin-2; Arthritis; Biological Assay; Biological Process; Blood Vessels; Cardiac; Coculture Techniques; Complex; Conditioned Culture Media; Data; Disease; Elements; Environment; Experimental Models; Eye diseases; Fractionation; Growth; Growth Factor; Hepatocyte Growth Factor; Human; Hypoxia; Implant; In Vitro; Inflammatory; Investigation; Malignant Neoplasms; Mediating; Mus; Oxygen; Pericytes; Peripheral Vascular Diseases; Pharmacotherapy; Phase; Proteins; Proteomics; Rattus; Reagent; Rodent; Role; Source; Stromal Cells; System; Technology; Testing; Tissues; Vascular Endothelial Growth Factors; angiogenesis; autocrine; base; cell behavior; cost effectiveness; efficacy testing; in vivo; member; paracrine; pre-clinical; public health relevance; research and development; research study; response; skin disorder

DESCRIPTION (provided by applicant): Human Microvessel Culture System (hMCS) Angiogenesis-targeting therapies, either inhibiting or promoting new vessel growth, have the potential for treating numerous diseases including cancer, eye diseases, cardiac and peripheral vascular disease, skin disorders, fibro-proliferative diseases, and inflammatory conditions such as arthritis. Furthermore, growing evidence indicates that for many of these diseases combinations of agents targeting multiple different vascular activities are proving more efficacious. As demand and complexity increases for these therapies, there is a growing need for more informative assays of relevant vascular growth and stability. Ideally, such an assay should recapitulate as much of the in vivo biological process as possible, while maintaining experimental simplicity and cost effectiveness. Angiomics, Inc. was founded on proven technology based on the manipulation and culturing of isolated microvessels from a variety of tissues. Utilizing rodent sources, this microvessel culture system has been used extensively and effectively as a more comprehensive experimental and discovery platform for a variety of vascular-related activities and therapies. Because the system utilizes intact microvessels, angiogenesis is more accurately recapitulated in both the culture and in vivo settings. In this system, true neovessels sprout and grow from intact microvessels within a 3-D matrix environment. Consequently, all angiogenesis-relevant activities/elements including perivascular cell behavior are present and integrated in the assay. The overall objective of this proposal is to adapt this proven and versatile microvessel culture system to support human microvessel viability and activity to add utility and value to the platform. It is guided by two Objectives tha 1) identify media components, guided by the rodent system, and 2) evaluate combinations of candidate growth factors or hypoxia factors that will support human microvessel viability and angiogenesis in culture.

描述(申请人提供)：人类微血管培养系统(HMCS)血管生成靶向疗法，抑制或促进新血管生长，具有治疗多种疾病的潜力，包括癌症、眼病、心脏和外周血管疾病、皮肤疾病、纤维增生性疾病和炎症条件，如关节炎。此外，越来越多的证据表明，对于许多此类疾病，针对多种不同血管活动的药物组合被证明更有效。随着对这些疗法的需求和复杂性的增加，对相关血管生长和稳定性的更多信息分析的需求也越来越大。理想情况下，这样的检测应该尽可能地概括体内的生物过程，同时保持实验的简单性和成本效益。血管组学公司建立在成熟的技术基础上，该技术基于对各种组织中分离的微血管的操纵和培养。利用啮齿动物资源，这种微血管培养系统已被广泛和有效地用作更全面的实验和发现平台，用于各种与血管相关的活动和治疗。由于该系统使用完整的微血管，因此在培养和体内环境中都可以更准确地再现血管生成。在这个系统中，真正的新生血管在3-D基质环境中从完整的微血管萌发和生长。因此，所有与血管生成相关的活动/元素，包括血管周围细胞的行为，都存在并整合在检测中。这项提议的总体目标是 调整这一成熟和多功能的微血管培养系统，以支持人类微血管的生存和活动，为平台增加实用性和价值。它以两个目标为指导：1)在啮齿动物系统的指导下，确定介质成分；2)评估支持人类微血管活性和培养中血管生成的候选生长因子或缺氧因子的组合。